- Home
- ESPR vs CCCC Comparison
ESPR vs CCCC Comparison
Compare ESPR & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- CCCC
- Stock Information
- Founded
- ESPR 2008
- CCCC 2015
- Country
- ESPR United States
- CCCC United States
- Employees
- ESPR N/A
- CCCC N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- CCCC Biotechnology: Pharmaceutical Preparations
- Sector
- ESPR Health Care
- CCCC Health Care
- Exchange
- ESPR Nasdaq
- CCCC Nasdaq
- Market Cap
- ESPR 399.0M
- CCCC 396.0M
- IPO Year
- ESPR 2013
- CCCC 2020
- Fundamental
- Price
- ESPR $2.32
- CCCC $4.00
- Analyst Decision
- ESPR Buy
- CCCC Buy
- Analyst Count
- ESPR 5
- CCCC 6
- Target Price
- ESPR $7.30
- CCCC $10.67
- AVG Volume (30 Days)
- ESPR 8.5M
- CCCC 1.9M
- Earning Date
- ESPR 11-07-2024
- CCCC 02-20-2025
- Dividend Yield
- ESPR N/A
- CCCC N/A
- EPS Growth
- ESPR N/A
- CCCC N/A
- EPS
- ESPR N/A
- CCCC N/A
- Revenue
- ESPR $295,451,000.00
- CCCC $33,668,000.00
- Revenue This Year
- ESPR $186.90
- CCCC $75.79
- Revenue Next Year
- ESPR $31.10
- CCCC N/A
- P/E Ratio
- ESPR N/A
- CCCC N/A
- Revenue Growth
- ESPR 187.12
- CCCC 65.45
- 52 Week Low
- ESPR $1.58
- CCCC $3.61
- 52 Week High
- ESPR $3.94
- CCCC $11.88
- Technical
- Relative Strength Index (RSI)
- ESPR 45.30
- CCCC 43.80
- Support Level
- ESPR $2.12
- CCCC $3.73
- Resistance Level
- ESPR $2.54
- CCCC $4.21
- Average True Range (ATR)
- ESPR 0.33
- CCCC 0.46
- MACD
- ESPR -0.09
- CCCC 0.02
- Stochastic Oscillator
- ESPR 22.86
- CCCC 26.17
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecular medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.